Metropolitan Life Insurance Company (MetLife)’s Kindred Biosciences, Inc. KIN Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio KIN Stock Details KIN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6,113	Closed	-$24.5K	–	2620
2020 Q1	$24.5K	Sell	6,113 -7,527	-55%	-$63.9K	﹤0.01%	2430
2019 Q4	$116K	Sell	13,640 -300	-2%	-$2.34K	﹤0.01%	2250
2019 Q3	$95.5K	Buy	13,940 +3,337	+31%	+$24.5K	﹤0.01%	2326
2019 Q2	$88.3K	Buy	10,603 +956	+10%	+$8.25K	﹤0.01%	2371
2019 Q1	$88.5K	Hold	9,647	–	–	﹤0.01%	2387
2018 Q4	$106K	Hold	9,647	–	–	﹤0.01%	2232
2018 Q3	$135K	Hold	9,647	–	–	﹤0.01%	2273
2018 Q2	$103K	Buy	+9,647	New	+$94.1K	﹤0.01%	2302
2014 Q3	–	Sell	-8,771	Closed	-$163K	–	2752
2014 Q2	$163K	Buy	+8,771	New	+$149K	﹤0.01%	2626

Other funds holding KIN

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s KIN Position: Q2 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Kindred Biosciences, Inc. (KIN) in Q2 2020, closing a stake of 6,113 shares — an estimated $24.5K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in KIN in Q2 2014 and held it in 9 quarters. The position peaked at $163K in Q2 2014. 83 funds tracked by Wall St. Rank hold KIN as of Q2 2020.

Metropolitan Life Insurance Company (MetLife) reported no remaining Kindred Biosciences, Inc. position as of Q2 2020 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 6,113 Kindred Biosciences, Inc. shares in Q2 2020, an estimated $24.5K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Kindred Biosciences, Inc. in Q2 2014 and held it in 9 quarters.
Metropolitan Life Insurance Company (MetLife)'s Kindred Biosciences, Inc. position peaked at $163K in Q2 2014.
83 funds tracked by Wall St. Rank held Kindred Biosciences, Inc. as of Q2 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2020, filed 14 Aug 2020.